CLAIMS

1   1.   A recombinant single chain polynucleotide comprising a region encoding the variable region of the light chain of an anti-G_{D2} antibody linked to a region encoding the variable region of the heavy chain of an anti-G_{D2} antibody.

2.   The recombinant polynucleotide of claim 1, further comprising a region encoding an additional protein.

3.   The recombinant polynucleotide of claim 1, wherein the additional protein is streptavidin.

4.   The recombinant polynucleotide of claim 1, wherein the additional protein is a drug-converting enzyme.

5.   A recombinant single chain peptide comprising the variable region of the light chain of an anti-G_{D2} antibody linked to the variable region of the heavy chain of an anti-G_{D2} antibody.

6.   The peptide according to claim 5, wherein the peptide is labeled with a radiolabel.

7   The peptide according to claim 6, wherein the radiolabel is ^{99m}Tc.

8.   The peptide according to claim 5, wherein the peptide further comprises a drug-converting enzyme.

9.   The peptide according to claim 5, wherein the peptide further comprises streptavidin.

1   10.   The peptide according to claim 5, wherein the peptide further
2   comprises CD8.

1   11.   T cells expressing a recombinant single chain peptide comprising the
2   variable region of the light chain of an anti-G_{D2} antibody linked to the variable region of the
3   heavy chain of an anti-G_{D2} antibody.

1   12.   A method for assaying for the presence of cells expressing G_{D2} in tissue
2   comprising combining the tissue with a recombinant single chain peptide comprising the
3   variable region of the light chain of an anti-G_{D2} antibody linked to the variable region of the
4   heavy chain of an anti-G_{D2} antibody and a detectable label.

1   13.   A method for targeted delivery of a therapeutic agent to cells
2   expressing G_{D2} in tissue comprising combining the tissue with a recombinant single chain
3   peptide comprising the variable region of the light chain of an anti-G_{D2} antibody linked to the
4   variable region of the heavy chain of an anti-G_{D2} antibody and a therapeutic or pre-therapeutic
5   moiety.

1   14.   The method according to claim 13, wherein the pre-therapeutic moiety
2   is a pro-drug converting enzyme.

1   15.   The method according to claim 13, wherein the pre-therapeutic moiety
2   is streptavidin.

1   16.   The method according to claim 13, wherein the therapeutic moiety is a
2   toxin.